1-20 of 28
Lawrence Fong
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract LB346: Mapping of shared tumor antigen reactivity with nanoparticle encapsulated mRNA in prostate cancer patients

Elena Montauti, Ole Haabeth, Chris Rae, Samuel Deutsch, Lawrence Fong, David Oh
Journal: Cancer Research
Cancer Res (2023) 83 (8_Supplement): LB346.
https://doi.org/10.1158/1538-7445.AM2023-LB346
Published: 14 April 2023
View article titled, Abstract LB346: Mapping of shared tumor antigen reactivity with nanoparticle encapsulated mRNA in prostate cancer patients
Journal Articles

Abstract 1120: Dissecting tumor cell programs through group biology estimation in clinical single-cell transcriptomics

Shreya Johri, Kevin Bi, Breanna M. Titchen, Jingxin Fu, Jake Conway, Jett Crowdis, Natalie I. Volkes, Zenghua Fan, Lawrence Fong, Jihye Park, David Liu, Meng Xiao He, Eliezer M. Van Allen
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 1120.
https://doi.org/10.1158/1538-7445.AM2023-1120
Published: 04 April 2023
View article titled, Abstract 1120: Dissecting tumor cell programs through group biology estimation in clinical single-cell transcriptomics
Journal Articles

Abstract 6420: Harnessing immune responses in prostate MMRd tumors treated with immune checkpoint blockade

Marcel Arias Badia, Zenghua Fan, Yee May Lwin, PeiXi Chen, Aahir Srinath, Lawrence Fong
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 6420.
https://doi.org/10.1158/1538-7445.AM2023-6420
Published: 04 April 2023
View article titled, Abstract 6420: Harnessing immune responses in prostate MMRd tumors treated with immune checkpoint blockade
Journal Articles

The 5-Hydroxymethylcytosine Landscape of Prostate Cancer

Martin Sjöström, Shuang G. Zhao, Samuel Levy, Meng Zhang, Yuhong Ning, Raunak Shrestha, Arian Lundberg, Cameron Herberts, Adam Foye, Rahul Aggarwal, Junjie T. Hua, Haolong Li, Anna Bergamaschi, Corinne Maurice-Dror, Ashutosh Maheshwari, Sujun Chen, Sarah W.S. Ng, Wenbin Ye, Jessica Petricca, Michael Fraser, Lisa Chesner, Marc D. Perry, Thaidy Moreno-Rodriguez, William S. Chen, Joshi J. Alumkal, Jonathan Chou, Alicia K. Morgans, Tomasz M. Beer, George V. Thomas, Martin Gleave, Paul Lloyd, Tierney Phillips, Erin McCarthy, Michael C. Haffner, Amina Zoubeidi, Matti Annala, Robert E. Reiter, Matthew B. Rettig, Owen N. Witte, Lawrence Fong, Rohit Bose, Franklin W. Huang, Jianhua Luo, Anders Bjartell, Joshua M. Lang, Nupam P. Mahajan, Primo N. Lara, Christopher P. Evans, Phuoc T. Tran, Edwin M. Posadas, Chuan He, Xiao-Long Cui, Jiaoti Huang, Wilbert Zwart, Luke A. Gilbert, Christopher A. Maher, Paul C. Boutros, Kim N. Chi, Alan Ashworth, Eric J. Small, Housheng H. He, Alexander W. Wyatt, David A. Quigley, Felix Y. Feng
Journal: Cancer Research
Cancer Res (2022) 82 (21): 3888–3902.
https://doi.org/10.1158/0008-5472.CAN-22-1123
Published: 02 November 2022
View article titled, The 5-Hydroxymethylcytosine Landscape of Prostate Cancer
Open the PDF for The 5-Hydroxymethylcytosine Landscape of Prostate Cancer in another window
Includes: Supplementary data
Journal Articles

Abstract CT301: A phase Ib study to evaluate RO7198457, an individualized Neoantigen Specific immunoTherapy (iNeST), in combination with atezolizumab in patients with locally advanced or metastatic solid tumors

Juanita S. Lopez, Ross Camidge, Marco Iafolla, Sylvie Rottey, Martin Schuler, Matthew Hellmann, Ani Balmanoukian, Luc Dirix, Michael Gordon, Ryan Sullivan, Brian S. Henick, Charles Drake, Kit Wong, Patricia LoRusso, Patrick Ott, Lawrence Fong, Aglaia Schiza, Jeffery Yachnin, Christian Ottensmeier, Fadi Braiteh, Johanna Bendell, Rom Leidner, George Fisher, Guy Jerusalem, Laura Molenaar-Kuijsten, Marcus Schmidt, Scott A. Laurie, Raid Aljumaily, Achim Rittmeyer, Eelke Gort, Ignacio Melero, Lars Mueller, Rachel Sabado, Patrick Twomey, Jack Huang, Manesh Yadav, Jingbin Zhang, Felicitas Mueller, Evelyna Derhovanessian, Ugur Sahin, Özlem Türeci, Thomas Powles
Journal: Cancer Research
Cancer Res (2020) 80 (16_Supplement): CT301.
https://doi.org/10.1158/1538-7445.AM2020-CT301
Published: 15 August 2020
View article titled, Abstract CT301: A phase Ib study to evaluate RO7198457, an individualized Neoantigen Specific immunoTherapy (iNeST), in combination with atezolizumab in patients with locally advanced or metastatic solid tumors
Journal Articles

Abstract 5672: Pharmacodynamics and potential predictive biomarkers of ABBV-428, a first-in-class mesothelin (MSLN)-CD40 bispecific, in patients with advanced solid tumors

Hua Fang, Shiming Ye, Anita Reddy, Tolga Turan, Andrew Woolley, Debra T. Chao, Cyril Ramathal, William R. Henner, Kinjal Hew, Michael McDevitt, Joel Hayflick, Frances Fan, Kathryn Allaire, Lawrence Fong
Journal: Cancer Research
Cancer Res (2020) 80 (16_Supplement): 5672.
https://doi.org/10.1158/1538-7445.AM2020-5672
Published: 15 August 2020
View article titled, Abstract 5672: Pharmacodynamics and potential predictive biomarkers of ABBV-428, a first-in-class mesothelin (MSLN)-CD40 bispecific, in patients with advanced solid tumors
Journal Articles

Abstract 5512: Identification of circulating myeloid cells induced in advanced biliary cancer patients responding to anti-PD1 through combined single cell RNA sequencing and protein expression analysis

Bridget P. Keenan, Elizabeth E. McCarthy, Arielle Ilano, David S. Lee, Yang Sun, Brenna Sheldon, Alexander Cheung, Chun Jimmie Ye, Robin Kate Kelley, Lawrence Fong
Journal: Cancer Research
Cancer Res (2020) 80 (16_Supplement): 5512.
https://doi.org/10.1158/1538-7445.AM2020-5512
Published: 15 August 2020
View article titled, Abstract 5512: Identification of circulating myeloid cells induced in advanced biliary cancer patients responding to anti-PD1 through combined single cell RNA sequencing and protein expression analysis
Journal Articles

Abstract CT098: KEYNOTE-046: Effects of ADXS-PSA with or without pembrolizumab on survival and antigen spreading in metastatic, castration-resistant prostate cancer patients

Mark Stein, Lawrence Fong, Ronald Tutrone, Anthony Mega, Elaine T. Lam, Surya Vangala, Justin Dennie, Robert Petit, Andres Gutierrez, Sandy Hayes, Naomi Haas
Journal: Cancer Research
Cancer Res (2019) 79 (13_Supplement): CT098.
https://doi.org/10.1158/1538-7445.AM2019-CT098
Published: 01 July 2019
View article titled, Abstract CT098: KEYNOTE-046: Effects of ADXS-PSA with or without pembrolizumab on survival and antigen spreading in metastatic, castration-resistant prostate cancer patients
Journal Articles

Abstract CT227: KEYNOTE-495/KeyImPaCT: Phase II biomarker-directed precision oncology study of pembrolizumab-based combination therapy for non-small cell lung cancer

Martin Gutierrez, Matthew D. Hellmann, Matthew Gubens, Charu Aggarwal, Daniel Shao Weng Tan, Enriqueta Felip, Joanne Wing Yan Chiu, Jong-Seok Lee, James Chih-Hsin Yang, Edward Garon, Andrea D. Basso, Hua Ma, Lawrence Fong, Alex Snyder, Jianda Yuan, Roy S. Herbst
Journal: Cancer Research
Cancer Res (2019) 79 (13_Supplement): CT227.
https://doi.org/10.1158/1538-7445.AM2019-CT227
Published: 01 July 2019
View article titled, Abstract CT227: KEYNOTE-495/KeyImPaCT: Phase II biomarker-directed precision oncology study of pembrolizumab-based combination therapy for non-small cell lung cancer
Journal Articles

Abstract 518: Hypoxia and high interstitial pressure present within the tumor microenvironment can promote T cell suppression and exhaustion

Chiara Rancan, Rachel Marusinec, James Lim, Lawrence Fong
Journal: Cancer Research
Cancer Res (2019) 79 (13_Supplement): 518.
https://doi.org/10.1158/1538-7445.AM2019-518
Published: 01 July 2019
View article titled, Abstract 518: Hypoxia and high interstitial pressure present within the tumor microenvironment can promote T cell suppression and exhaustion
Journal Articles

Abstract 550: Tumor-conditional anti-CTLA-4 uncouples anti-tumor efficacy from immunotherapy-related toxicity

Steven C. Pai, Donald M. Simons, Xiaoqing Lu, Wendy Ritacco, Michael Evans, Gillian Kingsbury, Lawrence Fong
Journal: Cancer Research
Cancer Res (2019) 79 (13_Supplement): 550.
https://doi.org/10.1158/1538-7445.AM2019-550
Published: 01 July 2019
View article titled, Abstract 550: Tumor-conditional anti-CTLA-4 uncouples anti-tumor efficacy from immunotherapy-related toxicity
Journal Articles

Abstract 4063: Single cell immune profiling of patients with advanced biliary cancers treated with combination checkpoint inhibition and GM-CSF reveals diverse T cell and myeloid cell mechanisms of action

Bridget P. Keenan, Whitney Tamaki, Eric Liu, Brandon Chen, Alexander Cheung, John D. Gordan, Brenna Sheldon, Li Zhang, Robin K. Kelley, Lawrence Fong
Journal: Cancer Research
Cancer Res (2019) 79 (13_Supplement): 4063.
https://doi.org/10.1158/1538-7445.AM2019-4063
Published: 01 July 2019
View article titled, Abstract 4063: Single cell immune profiling of patients with advanced biliary cancers treated with combination checkpoint inhibition and GM-CSF reveals diverse T cell and myeloid cell mechanisms of action
Journal Articles

Abstract 2981: Clonal deletion of tumor-specific T cells by combination checkpoint blockade compromises antitumor efficacy in low tumor burden states

Chien-Chun Steven Pai, Xiaoqing Lu, Donald Simons, Michel DuPage, Kole T. Roybal, Mingyi Chen, Serena Kwek, Amy-Jo Casbon, Gillian A. Kinsbury, Lawrence Fong
Journal: Cancer Research
Cancer Res (2018) 78 (13_Supplement): 2981.
https://doi.org/10.1158/1538-7445.AM2018-2981
Published: 01 July 2018
View article titled, Abstract 2981: Clonal deletion of tumor-specific T cells by combination checkpoint blockade compromises antitumor efficacy in low tumor burden states
Journal Articles

Abstract 4688: Single-cell discrimination of altered human T cell states in the bladder tumor microenvironment

David Yoonsuk Oh, Serena S. Kwek, Serghei Mangul, Siddharth S. Raju, Sasha Targ, Arun Burra, Eric Chow, Dvir Aran, Sima Porten, Maxwell V. Meng, Terence W. Friedlander, Chun Jimmie Ye, Lawrence Fong
Journal: Cancer Research
Cancer Res (2018) 78 (13_Supplement): 4688.
https://doi.org/10.1158/1538-7445.AM2018-4688
Published: 01 July 2018
View article titled, Abstract 4688: Single-cell discrimination of altered human T cell states in the bladder tumor microenvironment
Journal Articles

Abstract 1694: Systemic granulocyte-macrophage colony-stimulating factor (GM-CSF) treatment increases T cell receptor diversity in localized and metastatic prostate cancer patients

David Y. Oh, Li Zhang, Jason Cham, Alan Paciorek, Mark Klinger, Malek Faham, Susan F. Slovin, Lawrence Fong
Journal: Cancer Research
Cancer Res (2017) 77 (13_Supplement): 1694.
https://doi.org/10.1158/1538-7445.AM2017-1694
Published: 01 July 2017
View article titled, Abstract 1694: Systemic granulocyte-macrophage colony-stimulating factor (GM-CSF) treatment increases T cell receptor diversity in localized and metastatic prostate cancer patients
Journal Articles

Abstract CT119: CPI-444, an oral adenosine A2a receptor (A2aR) antagonist, demonstrates clinical activity in patients with advanced solid tumors

Leisha Emens, John Powderly, Lawrence Fong, Joshua Brody, Patrick Forde, Matthew Hellmann, Brett Hughes, Shivaani Kummar, Sherene Loi, Jason Luke, Daruka Mahadevan, Benjamin Markman, Ian McCaffery, Richard Miller, Ginna Laport
Journal: Cancer Research
Cancer Res (2017) 77 (13_Supplement): CT119.
https://doi.org/10.1158/1538-7445.AM2017-CT119
Published: 01 July 2017
View article titled, Abstract CT119: CPI-444, an oral adenosine A2a receptor (A2aR) antagonist, demonstrates clinical activity in patients with advanced solid tumors
Journal Articles

Abstract CT031: A phase Ib trial to study the safety and tolerability of atezolizumab with radium-223 dichloride in patients with metastatic castrate-resistant prostate cancer (mCRPC)

Lawrence Fong, Michael Morris, Andrew Armstrong, Daniel Petrylak, Ulka Vaishampayan, Ajjai Alva, Jean Hoffman-Censits, Indrani Sarkar, Susheela Carroll, Christina Schiff, Oliver Sartor
Journal: Cancer Research
Cancer Res (2017) 77 (13_Supplement): CT031.
https://doi.org/10.1158/1538-7445.AM2017-CT031
Published: 01 July 2017
View article titled, Abstract CT031: A phase Ib trial to study the safety and tolerability of atezolizumab with radium-223 dichloride in patients with metastatic castrate-resistant prostate cancer (mCRPC)
Journal Articles

Abstract 549: Clustering analysis of next-generation sequencing T cell repertoire data in sipuleucel-T treated prostate cancer patients

Li Zhang, Sounak Chakraborty, Jason Cham, David Oh, Nadeem Sheikh, Lawrence Fong
Journal: Cancer Research
Cancer Res (2017) 77 (13_Supplement): 549.
https://doi.org/10.1158/1538-7445.AM2017-549
Published: 01 July 2017
View article titled, Abstract 549: Clustering analysis of next-generation sequencing T cell repertoire data in sipuleucel-T treated prostate cancer patients
Journal Articles

Immune Toxicities Elicted by CTLA-4 Blockade in Cancer Patients Are Associated with Early Diversification of the T-cell Repertoire

David Y. Oh, Jason Cham, Li Zhang, Grant Fong, Serena S. Kwek, Mark Klinger, Malek Faham, Lawrence Fong
Journal: Cancer Research
Series: Author Choice
Cancer Res (2017) 77 (6): 1322–1330.
https://doi.org/10.1158/0008-5472.CAN-16-2324
Published: 14 March 2017
View article titled, Immune Toxicities Elicted by CTLA-4 Blockade in Cancer Patients Are Associated with Early Diversification of the T-cell Repertoire
Open the PDF for Immune Toxicities Elicted by CTLA-4 Blockade in Cancer Patients Are Associated with Early Diversification of the T-cell Repertoire in another window
Includes: Supplementary data
Journal Articles

Abstract CT134: Intratumoral electroporation of plasmid IL-12 can prime response to anti-PD1/PD-L1 blockade in patients with Stage III/IV-M1a melanoma

Alain Algazi, Katy K. Tsai, Kathryn T. Takamura, Lawrence Chen, Chris Twitty, Mary Dwyer, Samantha Greaney, Tu Diep, Robert H. Pierce, Mai H. Le, Lawrence Fong, Adil Daud
Journal: Cancer Research
Cancer Res (2016) 76 (14_Supplement): CT134.
https://doi.org/10.1158/1538-7445.AM2016-CT134
Published: 15 July 2016
View article titled, Abstract CT134: Intratumoral electroporation of plasmid IL-12 can prime response to anti-PD1/PD-L1 blockade in patients with Stage III/IV-M1a melanoma